Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

10812	Companies
234240	Keywords
163037	Articles
125255	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 10/23/2025 at 08:00, 9 months 16 days ago

THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million
THX Pharma launches a €8 million capital increase to fund rare neurological drug development, with 75.5% commitments secured. Batten-1 and TX01 to lead clinical and commercial endeavors with strategic shift to international markets. Investment opportunities for various tax schemes

Investment Capital Increase Drug Development Neurological Diseases THX Pharma
BRIEF

published on 10/14/2025 at 18:35, 9 months 24 days ago

THX Pharma et Exeltis progressent vers la mise sur le marché de TX01

Commercialisation Maladies Rares Exeltis TX01 THX Pharma
BRIEF

published on 10/14/2025 at 18:35, 9 months 24 days ago

THX Pharma and Exeltis Advance Toward Commercialization of TX01

Marketing Rare Diseases Exeltis TX01 THX Pharma
PRESS RELEASE

published on 10/14/2025 at 18:30, 9 months 24 days ago

THX PHARMA (THERANEXUS) ET EXELTIS FRANCHISSENT UNE ÉTAPE MAJEURE VERS LA COMMERCIALISATION DE TX01
THX Pharma (Theranexus) et Exeltis franchissent une étape majeure vers la commercialisation de TX01 pour les maladies de Gaucher et de Niemann-Pick de type C. Annonce du dépôt du dossier réglementaire et avancement vers la mise à disposition du traitement pour les patients

Commercialisation Maladies Rares Exeltis TX01 THX Pharma
PRESS RELEASE

published on 10/14/2025 at 18:30, 9 months 24 days ago

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
THX Pharma (Theranexus) and Exeltis achieve key milestone towards the commercialization of TX01 for rare neurological diseases, including Gaucher and Niemann-Pick type C. A pivotal step towards regulatory submission and global launch

Commercialization Neurological Diseases Exeltis TX01 THX Pharma
BRIEF

published on 09/29/2025 at 18:35, 10 months 8 days ago

THX Pharma : une évolution stratégique vers l'international

Stratégie De Croissance Maladies Rares THX Pharma Commercialisation Internationale Médicaments TX01 Et Batten-1
BRIEF

published on 09/29/2025 at 18:35, 10 months 8 days ago

THX Pharma: a strategic evolution towards international expansion

Growth Strategy Rare Diseases THX Pharma International Marketing Drugs TX01 And Batten-1
PRESS RELEASE

published on 09/29/2025 at 18:30, 10 months 8 days ago

Theranexus devient THX Pharma : une évolution stratégique vers la commercialisation de ses médicaments dans les maladies rares
THX Pharma, anciennement Theranexus, annonce sa nouvelle phase stratégique axée sur l'enregistrement, l'accès précoce et la commercialisation internationale de ses médicaments

Candidats Médicaments Maladies Neurologiques Rares THX Pharma Commercialisation Internationale Enregistrement
PRESS RELEASE

published on 09/29/2025 at 18:30, 10 months 8 days ago

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases
THX Pharma (formerly Theranexus) announces strategic focus on regulatory approval, early access, and global commercialization of new drug candidates for rare neurological diseases

Regulatory Approval Commercialization Rare Neurological Diseases THX Pharma Early Access
BRIEF

published on 09/25/2025 at 18:05, 10 months 12 days ago

Theranexus publie ses résultats financiers du premier semestre 2025

Résultats Financiers Theranexus Batten-1 Réduction Coûts TX01

Accesswire

Published on 08/08/2026 at 00:00, 15 hours 24 minutes ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 16 hours 9 minutes ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 16 hours 24 minutes ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 16 hours 54 minutes ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 17 hours 9 minutes ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 23:21, 16 hours 3 minutes ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 19 hours 54 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 20 hours 9 minutes ago

ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 21 hours 14 minutes ago

Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 21 hours 24 minutes ago

E-PANGO: Composition du capital au 31 juillet 2026

Les Echos

Published on 08/07/2026 at 18:54, 20 hours 30 minutes ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 20 hours 30 minutes ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 20 hours 43 minutes ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 20 hours 43 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 21 hours 24 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE